Canada’s largest drugmaker is close to acquiring Bausch & Lomb Inc. in a roughly $9 billion deal, published reports state.
Valeant Pharmaceuticals International Inc. is seeking to acquire the local eye-care company owned by private-equity firm Warburg Pincus LLC, Bloomberg, Reuters and the Wall Street Journal reported Friday afternoon.
Warburg reportedly had been shopping Bausch & Lomb to a variety of companies early this year, and then filed for an initial public offering in March after the effort to sell the company for at least $10 billion stalled.
Valeant is seeking acquisitions of companies with solid cash flows in high-growth areas, CEO Mike Pearson said on a conference call with investors earlier this month, Bloomberg reported. The Bausch & Lomb deal would be the largest of 15 acquisitions for Montreal-based Valeant since it was created in a 2010 merger of its U.S. predecessor and Canada’s Biovail Corp.
Private equity firm Warburg Pincus bought Bausch & Lomb for $3.7 billion in September 2007, taking the longtime publicly traded company private.
Bausch & Lomb officials have declined to talk about possible acquisitions of the company.
In an interview with the Rochester Business Journal last July, Bausch & Lomb CEO Brent Saunders said an IPO was more likely than a sale.
The company has posted a loss in each of the last three years, the registration filing states. Its net losses in 2010-2012 attributable to Bausch & Lomb Holdings were $196 million, $123.9 million and $68.3 million, respectively.
Net sales rose from $937.2 million in 2010 to $1.3 billion in 2012.
Bloomberg projected that at $9 billion including debt, Bausch & Lomb would be valued at about 21 times earnings before interest, taxes, depreciation and amortization of $429.5 million in the year through December.
5/24/13 (c) 2013 Rochester Business Journal. To obtain permission to reprint this article, call 585-546-8303 or email email@example.com.